Buy Or Sell Opportunity • Jun 06
Now 22% undervalued Over the last 90 days, the stock has risen 3.3% to €106. The fair value is estimated to be €136, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 30% per annum over the same time period. 공시 • May 07
An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million. An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem.
For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million.
An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. 공시 • Apr 22
Repligen Corporation to Report Q1, 2026 Results on May 05, 2026 Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026 공시 • Apr 03
Repligen Corporation, Annual General Meeting, May 14, 2026 Repligen Corporation, Annual General Meeting, May 14, 2026. 공시 • Feb 24
Repligen Corporation Provides Earnings Guidance for the Full Year 2026 Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share. 공시 • Feb 10
Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026 Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026 공시 • Jan 07
Repligen Corporation Announces Executive Changes, Effective March 13, 2026 On January 6, 2026, Repligen Corporation announced that the Board of Directors has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Dr. Madaus will succeed Tony J. Hunt, who is currently serving as the Executive Chair of the Board, following his previously announced March 2026 retirement, which shall be on the Effective Date, at which time Mr. Hunt will retire as a member of the Board. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta Inc. and Hologic Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany. 공시 • Dec 17
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows Repligen Corporation announced the launch of three new high-performance chromatography resins: AVIPure®? HiPer™? AAV9 and AVIPure®? Hi Per™? AAV8 affinity resins, along with HiPer™? QA anion-exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™? DuloCore™? base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026. Buy Or Sell Opportunity • Nov 06
Now 21% undervalued Over the last 90 days, the stock has risen 22% to €123. The fair value is estimated to be €155, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.2% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 45% per annum over the same time period. Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: US$0.27 (vs US$0.012 loss in 3Q 2024) Third quarter 2025 results: EPS: US$0.27 (up from US$0.012 loss in 3Q 2024). Revenue: US$188.8m (up 22% from 3Q 2024). Net income: US$14.9m (up US$15.6m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. 공시 • Oct 29
Repligen Corporation Updates Financial Guidance for the Full Year 2025 Repligen Corporation updated financial guidance for the full year 2025. For the year, the total reported revenue of $729 million to $737 million, Income from Operations of $50 million to $52 million, net income of $46.5 million to $48 million and Earnings per share - Diluted of $0.82 per share to $0.85 per share. 공시 • Oct 15
Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025 Repligen Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025 공시 • Jul 29
Repligen Corporation Updates Financial Guidance for the Full Year 2025 Repligen Corporation updated financial guidance for the full year 2025. For the year total reported revenue of $715 million to $735 million, Income from Operations of $51 million- $56 million, net income of $48 million - $51.5 million and Earnings per share - Diluted of $0.85 per share - $0.92 per share. 공시 • Jul 17
Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025 Repligen Corporation announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2025 